Drug-related hospital stays in Australia

Similar documents
Drug-related hospital stays in Australia

Drug related hospital stays in Australia

Accidental drug-induced deaths due to opioids in Australia, 2013

2002 AUSTRALIAN BUREAU OF STATISTICS DATA ON ACCIDENTAL DRUG-INDUCED DEATHS DUE TO OPIOIDS

Cocaine and Methamphetamine related drug-induced deaths in Australia, 2011

illicit drug reporting system drug trends bulletin Key findings from the 2015 IDRS: a survey of people who inject drugs Introduction

EMBARGOED NOT FOR RELEASE PRIOR TO AM WEDNESDAY OCTOBER

Key findings from the 2014 IDRS: a survey of people who inject drugs

OVERDOSE DEATHS IN AUSTRALIA COCAINE AND METHAMPHETAMINE MENTIONS IN ACCIDENTAL DRUG-INDUCED DEATHS IN AUSTRALIA,

Author: Laura A Scott and Lucy Burns, National Drug and Alcohol Research Centre, University of New South Wales

2014 Key Australian findings: psychostimulant drug market

An overview of the 2015 Ecstasy and Related Drugs. Reporting System. Ecstasy and Related Drugs. drug trends bulletin October 2015

Key findings for drug use patterns & drug markets

An overview of the 2014 Ecstasy and Related Drugs. Reporting System. Ecstasy and Related Drugs. drug trends bulletin October 2014

Ecstasy and Related Drugs Reporting System drug trends bulletin April 2013 Supplement

trends bulletin ecstasy and related drug Key findings An overview of the 2011 EDRS: What is happening to ecstacy and related drugs in Australia?

Ecstasy and Related Drugs Reporting System: 2016 Findings

S. O Brien, E. Black, L. Degenhardt, A. Roxburgh, G. Campbell, B. de Graaff, J. Fetherston, R. Jenkinson, S. Kinner, C. Moon and N.

What is Drug Trends? funded by the Australian Government under the Substance Misuse Prevention and Service Improvement Grants Fund

Overview of the Australian National Drug Strategy Household Survey (NDSHS)

Australian Drug Trends Key findings from the National Illicit Drug Reporting System (IDRS) Interviews

drug trends bulletin Driving behaviours among people who inject drugs in South Australia, Key findings december 2011 ISSN

Rise in LSD use among Regular Psychostimulant Users: Why the increase and is it a cause for concern?

ILLICIT DRUG REPORTING SYSTEM DRUG TRENDS BULLETIN

Cocaine. Key Points 60 ILLICIT DRUG DATA REPORT

Risks of alcohol-attributable hospitalisation and death in Australia over time: Evidence of divergence by region, age and sex

Methamphetamine Use in Australia: What the data tells us about patterns of use & users. methamphetamine

bulletin criminal justice Police drug diversion in Australia Key Points Jennifer Ogilvie and Katie Willis

Appendix 1: Data elements included in the AODTS NMDS for

Changing patterns of new and emerging psychoactive substances in Australia

AIHW Dental Statistics and Research Unit Research Report No. 26 Access to dental services among Australian children and adults

A Snapshot of Substance Use: Licit and Illicit Drug Use Yesterday among People Who Inject Drugs in Australia ( ).

Review of illicit drug use among Aboriginal and Torres Strait Islander people

Key findings from the 2014 Illicit Drug Reporting System

Emma Black and Louisa Degenhardt National Drug and Alcohol Research Centre University of New South Wales

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

Ecstasy and Related Drugs Reporting System drug trends bulletin July 2012

WELCOME TO THE CRACKS IN THE ICE WEBINAR SERIES

Plain language review of illicit drug use among Aboriginal and Torres Strait Islander people

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

AUSTRALIAN. Capital Territory. Kerryn Butler & Courtney Breen ACT DRUG TRENDS Findings from the. Illicit Drug Reporting System (IDRS)

Dental health differences between boys and girls

Cannabis. Key Points 36 ILLICIT DRUG DATA REPORT

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

Measuring the Illegal Drug Economy of Australia in a National Accounts Framework: Some Experimental Estimates Drug Policy Modelling Program Symposium

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

The data refer to persons aged between 15 and 54.

World Drug Report 2017

Deceased Organ Donation SECTION 2

KEY FINDINGS FROM THE NATIONAL ECSTASY AND RELATED DRUGS REPORTING SYSTEM (EDRS) INTERVIEWS

WORLD DRUG REPORT 2004 WORLD DRUG REPORT. presented by Thomas Pietschmann UNODC, Research and Analysis Section

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

The epidemiology of cannabis use and cannabis-related harm in Australia add_

Ecstasy and Related Drugs Reporting System drug trends bulletin April 2014

CHAPTER 4 METHOD AND LOCATION OF DIALYSIS. Nancy Briggs Kylie Hurst Stephen McDonald Annual Report 35th Edition

Epidemiology of non medical use of prescription drugs. Kamran Niaz, Survey and Statistics Section, Policy Analysis and Research Branch

Fairlie McIlwraith and Rosa Alati. QUEENSLAND DRUG TRENDS 2014 Findings from the Illicit Drug Reporting System (IDRS)

Amphetamine availability predicts amphetamine-related mental health admissions: A time series analysis

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCE Narrative

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

Cocaine Use Among a Sample of Police Detainees

NORTHERN TERRITORY DRUG TRENDS 2018: KEY FINDINGS FROM THE ECSTASY AND RELATED DRUGS REPORTING SYSTEM (EDRS) INTERVIEWS

CHAPTER 2. Prevalence of Renal Replacement Therapy for End Stage Kidney Disease

AUSTRALIAN. Capital Territory

A reduction in the availability of heroin in Australia

Annual Reports Questionnaire (ARQ) Part III: Extent, patterns and trends in drug use

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

SA Mental Health Commission 57 th Barton Pope Lecture

Taking Stock of the 2009 PoA Research and Trend Analysis Branch

AUSTRALIAN INFLUENZA SURVEILLANCE SUMMARY REPORT

2017 Drug Use Trends in King County, Washington

Statistics on Drug Misuse: England, 2008

Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander people: Annual Surveillance Report

AUSTRALIAN NSP SURVEY NATIONAL DATA REPORT

Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender,

State of Cardiovascular Health in the NT DR MARCUS ILTON

Legal thresholds for drug trafficking: Evaluating the risk of unjustified charge of users as traffickers in six Australian states

Statistics on Drug Misuse: England, 2007

CHAPTER 2. Prevalence of Renal Replacement Therapy for End Stage Kidney Disease

WORLD DRUG REPORT 2011

Developing a drug monitoring system for New Zealand: IDMS

MYANMAR. Emerging trends and concerns

Global drug trends and sustainable development

National Framework for Ethical Behaviour and Integrity in Basketball Appendix 3. Illicit Drugs Policy. Date adopted by BA Board 3 April 2017

STOCK and FLOW. ANZDATA Registry 2011 Report CHAPTER 1 STOCK & FLOW. Blair Grace Kylie Hurst Stephen McDonald 1-1

Annual report 2009: the state of the drugs problem in Europe

Drug Abuse Trends Minneapolis/St. Paul, Minnesota

Patterns of mephedrone, GHB, Ketamine and Rohypnol use among police detainees: Findings from the DUMA program

J. Fetherston and S. Lenton WA DRUG TRENDS 2017 Findings from the Illicit Drug Reporting System (IDRS) Australian Drug Trends Series No.

J. Fetherston and S. Lenton WA DRUG TRENDS 2012 Findings from the Illicit Drug Reporting System (IDRS) NDARC Technical Report No.

Ecstasy and Related Drugs Reporting System drug trends bulletin

[ ASSESSING THE BURDEN OF ILLICIT DRUGS AND ALCOHOL ABUSE:] Macomb County Office of Substance Abuse. A Focus on Heroin and Prescription Drug Abuse

Amphetaminetype. Key Points

60 Y BC DOAP REPORT 2014

Illicit manufacture of methamphetamine, primarily in pill form (yaba), continues, particularly in the Shan, Wa, and Kokang autonomous region.

Drug Threat Summaries of Designated Areas

Transcription:

Drug-related hospital stays in Australia 1993-213 Prepared by Amanda Roxburgh and Lucinda Burns, National Drug and Alcohol Research Centre Funded by the Australian Government Department of Health Introduction This bulletin presents data on drug-related hospital separations in Australia from 1993-213 for the following drug types: opioids, cocaine, amphetamines and cannabis. A hospital separation is defined as an episode of care for an admitted patient, which may refer to a total hospital stay (from admission to discharge), or a portion of a hospital stay beginning or ending in a change of type of care, or transfer to another hospital. At the time of separation, a principal (main) diagnosis, and up to 4 secondary diagnoses may be made. The data presented in this bulletin include only hospital separations where opioids, cocaine, amphetamines or cannabis were determined to be the principal (i.e. main) reason for the hospital stay. The data presented will therefore be an under-estimate of the total number of drug-related hospital admissions. Hospital separations are coded according to the World Health Organization s (WHO) International Statistical Classification of Diseases (ICD) and Related Problems. The ICD 1th revision (ICD 1 AM) (National Centre for Classification in Health, 1998) was used to code data dating from 1999 to the present in South Australia (SA), Western Australia (WA), and Queensland (QLD). The remaining jurisdictions commenced using ICD 1 AM codes in 1998. Prior to this, the ICD 9th revision (ICD 9 CM) (National Coding Centre, 1996) was used to code hospital separations. Appendix A provides the ICD codes used for this analysis. As problems associated with drug use occur largely in youth to middle age, hospital separations are presented as numbers per million persons aged 15-54, calculated using the Australian Bureau of Statistics estimated resident population figures as at 3 June each year. All figures referred to in this bulletin are rates per million population. It should be noted that variations in coding practices may exist across jurisdictions. Figure 1 shows the rates of hospital separations per million persons for each of the four drug types over the 2 year time period (1993-213). Rates were highest for opioids across the entire period, followed by amphetamines and cannabis, then cocaine. 1

Figure 1: Rates per million persons of principal drug-related hospital separations in Australia among persons aged 15-54, by drug type, 1993-213 9 8 7 6 5 4 3 2 1 opioids amphetamines cocaine cannabis Opioid-related hospital separations For the purposes of this bulletin, opioid-related hospital separations are defined as those separations where opioids were recorded as the principal diagnosis. See Appendix A for the ICD codes used in this analysis. Trends over time Opioid-related hospital separations have slowly increased over time since the decline seen in 21/2 (Figure 2). There were 433 separations per million persons recorded in 212/13. In 212/13, opioid dependence accounted for approximately half (53%) of all principal opioid-related separations in Australia. This represents a decline from approximately twothirds of separations that were due to dependence through the 199s. Over time there has been an increase in separations due to poisoning from opioids other than heroin (including morphine, oxycodone, and codeine) which accounted for 19% of all opioid-related separations in 212/13 (these poisonings accounted for 7% of all opioidrelated separations in 2/1). Separations due to heroin poisoning comprised 9% of all opioid-related separations in 212/13 among Australians aged 15 to 54. Age analysis In 212/13, the 3 to 39 year age group accounted for the largest proportion (32%) of opioid-related separations. Over time, there were different trends apparent across different age groups. Separations among older Australians (3 to 39, and 4 to 49 year olds) have increased since 21/2, while remaining relatively stable among those aged 1 to 29 years. Opioid-related separations were lowest among Australians aged 1 to 19 years (data not shown). Jurisdictional analysis Opioid-related separations for the most part have been highest in New South Wales (NSW) over the 2 year period (62 separations per million persons were recorded in 212/13). Separations in NSW trended downwards between 26/7 and 29/1, with an upward trend evident over the past 3 years (Figure 2). 2

Separations in Queensland (QLD) were the next highest and show an upward trend over the past 3 years (462 separations per million persons were recorded in 212/13). Western Australia (WA) also recorded relatively high rates of opioid-related separations (399 separations per million persons in 212/13), and these separations have declined over the past two years. Victoria (VIC) and South Australia (SA) have recorded declines in opioid-related separations in the past year (28 and 283 per million persons respectively in 212/13). Separations in Tasmania (TAS) have stabilised at 265 per million persons in the past year, while trends in the Northern Territory (NT) and the Australian Capital Territory (ACT) have fluctuated at lower levels (Figure 2). Trends in other data At the national level, the proportion of participants from the Illicit Drug Reporting System (IDRS) across Australia reporting having recently injected morphine has declined (Stafford and Burns in press). With the exception of the NT, where daily morphine injection was common, and QLD and TAS (use was approximately twice weekly), patterns of morphine injecting was sporadic across Australia (Stafford and Burns in press). The prevalence of oxycodone injection among people who inject drugs has stabilised over the past few years (this figure was 31% in 213 and 28% in 214), and patterns of use are much more sporadic than those for morphine. NSW participants reported the most frequent injection of oxycodone over the past 6 months at just under once per week on average, while the national average was reported as fortnightly injection (Stafford and Burns in press). Figure 2: Rates per million persons of principal opioid-related hospital separations in Australia among persons aged 15-54, 1993-213 14 12 1 8 6 4 2 NSW VIC QLD SA WA TAS NT ACT National 3

Amphetamine-related hospital separations For the purposes of this bulletin, amphetamine-related hospital separations are defined as those separations where amphetamines were recorded as the principal diagnosis. See Appendix A for the ICD codes used in this analysis. Amphetamine-related hospital separations include separations for ecstasy. Trends over time The 212/13 amphetamine-related separations represented the highest number recorded at 3,481 separations. Separations steadily increased since the mid 9 s, and peaked at 18 per million persons in 23/4 and again at 19 in 26/7. Over the past 4 years amphetamine-related separations have trended upwards. There were 272 separations per million persons recorded in 212/13. Over time, separations for amphetamine dependence have accounted for an increasing proportion of all amphetamine-related separations in Australia, (from 3% in 1999/ to 5% in 212/13). Separations for amphetamine-related psychosis steadily increased to 25/6 and have increased again since 29/1 across all jurisdictions (Figure 4). Age analysis Over time, amphetamine-related separations have been highest among the 2 to 29 year age group, followed by the 3 to 39 year age group. However, separations among the older age groups (2 to 29, 3 to 39 and 4 to 49 year olds) have increased over the last three years (data not shown). Separations among the 1 to 19 year olds in 212/13 (at 442) were highest over the 2 year period. In 212/13 amphetamine-related psychosis separations were highest among the 2 to 29 and 3 to 39 year age groups. Jurisdictional analysis Over the past three years amphetamine-related separations were at the highest level to date in WA, NSW and VIC (at 36, 333, and 245 per million persons respectively Figure 3). TAS and the ACT recorded the lowest rates of amphetamine-related separations relative to the other jurisdictions (at 57 and 136 separations per million persons respectively Figure 3). In 212/13 amphetamine-related psychosis separations were highest in WA, SA and NSW (at 297, 23 and 184 separations per million persons respectively Figure 4). Trends in other data Law enforcement data are consistent with the noted increase in amphetamine-related hospital separations. The Australian Customs and Border Protection Service detected a record number (2,1) of amphetamine-type-stimulant seizures, with a record weight, in 212/13 (Australian Customs and Border Protection Service, 214). The Australian Crime Commission documented a high number of clandestine laboratories detected (757) in 212/13, with the majority manufacturing methamphetamine (Australian 4

Crime Commission, 214). Trends among a sentinel group of people who inject drugs (surveyed for the Illicit Drug Reporting System IDRS) showed an increase in the prevalence of crystal methamphetamine use in the past 6 months (Sindicich and Burns in press). Data from the 213 National Drug Strategy Household Survey (NDSHS) showed that although the prevalence of past year methamphetamine use remained stable at 2.1% in the general population, there was a change in the main form used from powder to crystalline (51% in 21 reported mostly using powder methamphetamine compared to 29% in 213, and 22% in 21 reported mostly using crystal methamphetamine compared to 5% in 213). There has also been a significant increase in the proportion of methamphetamine users reporting weekly or more often methamphetamine use (from 9.3% in 21 to 15.5% in 213) (http://www.aihw.gov.au/alcohol-and-other-drugs/ndshs/213/illicit-drug-use/#illicit). Figure 3: Rates per million persons of principal amphetamine-related hospital separations in Australia among persons aged 15-54, 1993-213 4 35 3 25 2 15 1 5 NSW VIC QLD SA WA TAS NT ACT National NB: These figures do not include amphetamine-psychosis separations. These are reported separately in Figure 4. 5

Figure 4: Rates per million persons of amphetamine-psychosis hospital separations in Australia among persons aged 15-54, 1999-213 4 35 3 25 2 15 1 5 NSW VIC QLD SA WA TAS NT ACT National NB: Amphetamine-psychosis separations in WA may be overestimated due to a new facility joining the collection in 21, and different coding practices employed. However, other amphetamine separations reported in Figure 3 show an increasing trend in WA. Cannabis-related hospital separations For the purposes of this bulletin, cannabis-related hospital separations are defined as those separations where cannabis was recorded as the principal diagnosis. See Appendix A for the ICD codes used in this analysis. Trends over time Cannabis-related separations have steadily increased since 1993/94, with figures recorded in 212/13 representing the highest over the entire period (at 186 separations per million persons - Figure 5). Separations for cannabis dependence accounted for an increasing proportion of all cannabis-related separations in Australia, from 55% in 1999/ to 72% in 212/13. Separations for cannabis-related psychosis increased across most jurisdictions to 25/6. While they have since declined in most jurisdictions, they have stabilised at a higher rate in NSW and SA (Figure 6). Age analysis In 212/13, the 2 to 29 year age group accounted for the largest proportion (39%) of all cannabis-related separations, and these were primarily for dependence (71%) (data not shown). Steady increases in cannabis-related separations have been recorded among older Australians (aged 3 to 49 years) over the past ten years. Cannabis-related separations among the 1 to 19 year olds remain lower, although 6

separations have started to increase over the past 5 years (data not shown). In 212/13 cannabis-related psychosis separations were highest among the 2 to 29 year age group. Jurisdictional analysis Cannabis-related separations have remained consistently highest in NSW. Steady increases have been recorded in NSW since 1993/94 (from 55 per million persons in 1993/94 to 335 separations per million persons in 212/13) (Figure 5). This increase has largely been driven by cannabis dependence, (83% of cannabis-related separations in NSW in 212/13). TAS recorded the second highest rates of cannabis-related separations. The increase to 212/13 was driven by separations for harmful cannabis use (accounting for 58% of the separations). QLD, SA and WA recorded increases in cannabis-related separations over the past six years, while trends have fluctuated in the remaining jurisdictions (Figure 5). NT recorded the highest rate of cannabis-related psychosis separations across the time period, however these separations have declined dramatically since 25/6 (Figure 6). The NT figures should be interpreted with caution. It appears that most cannabis separations in the NT are coded under the psychosis code, so the high rates may reflect differences in coding practices across jurisdictions. There are virtually no non-psychosis cannabis related separations recorded in the NT. Trends in other data The 213 National Drug Strategy Household Survey reported a stable trend in past year prevalence of cannabis use among Australians at 1.2% (Australian Institute of Health and Welfare, 214). Figure 5: Rates per million persons of principal cannabis-related hospital separations in Australia among persons aged 15-54, 1993-213 4 35 3 25 2 15 1 5 NSW VIC QLD SA WA TAS NT ACT National NB: These figures do not include cannabis-psychosis separations. These are reported separately in Figure 6. 7

Figure 6: Rates per million persons of principal cannabis-psychosis hospital separations in Australia among persons aged 15-54, 1999-213 6 5 4 3 2 1 NSW VIC QLD SA WA TAS NT ACT National NB: High rates of cannabis-psychosis in the NT may be due to different coding practices. There are virtually no nonpsychosis cannabis related separations recorded in the NT, suggesting most cannabis separations may be recorded as cannabis-psychosis. Cocaine-related hospital separations For the purposes of this bulletin, cocaine-related hospital separations are defined as those separations where cocaine was recorded as the principal diagnosis. See Appendix A for the ICD codes used in this analysis. Trends over time Cocaine-related separations were the lowest across the four drug types during the twentyyear period (Figure 7). Separations increased between 1993/94 and 24/5 (peaking at 22 per million persons). Separations were the highest on record in 212/13 at 28 separations per million persons. Age analysis The 3 to 39 year age group continued to account for the largest proportion of cocainerelated separations (36% in 212/13) followed by the 2 to 29 year olds (27%). Jurisdictional analysis NSW recorded the highest number of cocaine-related separations (75 per million persons in 212/13) during the entire period. Separations in NSW almost doubled between 211/12 and 212/13 (from 38 to 75 separations per million persons respectively). In 212/13 approximately two-thirds (68%) of NSW cocaine-related separations were for dependence. The remaining jurisdictions recorded much lower numbers of cocaine-related separations throughout the time period. 8

Trends in other data The trends seen in cocaine-related hospital separations in NSW are consistent with trends in cocaine use among people surveyed for both the IDRS and EDRS (Sindicich and Burns, 213, Stafford and Burns, 213), with use being most prevalent in NSW. Trends in cocaine-related separations should be interpreted with caution due to relatively small numbers in many jurisdictions. Figure 7: Rates per million persons of principal cocaine-related hospital separations in Australia among persons aged 15-54, 1993-213 8 7 6 5 4 3 2 1 NSW VIC QLD SA WA TAS NT ACT National 9

Summary and Implications Opioid-related separations have been steadily increasing since 25/6, with increases noted both in presentations for other opioid poisoning (for substances including morphine, codeine and oxycodone) and for opioid dependence. The number of amphetamine-related hospital separations recorded in 212/13 (3,481) is the highest since 1993/94. These separations have steadily increased over the past 3 years. An increasing proportion of amphetamine-related separations have been for amphetamine dependence (5% in 212/13), indicative of more chronic and problematic use among those who are presenting. Amphetamine-related separations among the 1 to 19 year olds were the highest on record in 212/13, and were predominantly for acute effects related to amphetamine use, such as poisonings and acute intoxication. Cannabis-related separations in 212/13 were the highest on record since 1993/94. Presentations for cannabis dependence accounted for an increasingly large proportion of cannabis-related separations (from 55% in 1999/ to 72% in 212/13). Cannabis-related separations were most prevalent among the 2 to 29 year age group, most commonly for cannabis dependence, suggesting heavy cannabis use and associated harms among the younger age groups. Cocaine-related separations in NSW continue to account for the majority of separations nationally and have remained relatively high over the past eight years. This trend is consistent with significant increases in past year cocaine use recorded in the National Drug Strategy Household Survey (Australian Institute of Health and Welfare, 211). Information contained in this bulletin comes from the National Hospital Morbidity Database. This database is fundamental to the monitoring capacity of the National Illicit Drug Indicators Project. These data provide invaluable information about trends in drug-related harms in Australia, as well as the context within which these trends can be understood. Each additional year of data adds further value to the project and, in conjunction with other available data sources, provides a reliable framework within which to inform evidence-based drug policy in Australia. Acknowledgements We would like to acknowledge the Australian Institute of Health and Welfare, and all of the State and Territory Health Departments, for providing us with access to the National Hospital Morbidity Database. 1

Appendix A: Opioid-related hospital separations The following ICD-9-CM (from 1993/94 to 1998/99) and ICD-1-AM (from 1999/ to 27/8) codes were used to examine trends in opioid-related hospital separations: ICD-9 diagnosis ICD-1 diagnosis ICD-9-CM ICD-1-AM Opium poisoning Opium poisoning 965 T4 Heroin poisoning Heroin poisoning 9651 T41 Methadone poisoning Methadone poisoning 9652 T43 Morphine/codeine/pethidine poisoning Other opioids poisoning 9659 T42 (including morphine, codeine, oxycodone) Morphine/codeine/pethidine poisoning Other synthetic narcotics poisoning 9659 T44 (including pethidine) Morphine/codeine/pethidine poisoning Other and unspecified narcotics 9659 T46 poisoning Opioid type dependence Opioid dependence syndrome 34 F112 (including heroin, methadone, morphine, opium) Opioid and other drug dependence No equivalent 347 N/A Opioid use disorder Opioid acute intoxication 355 F11 Opioid use disorder Opioid harmful use 355 F111 Note: Withdrawal codes for ICD-9-CM were not drug specific, and accordingly, for comparability purposes, these separations have been left out of the analysis. Amphetamine-related hospital separations The following ICD-9-CM (from 1993/94 to 1998/99) and ICD-1-AM (from 1999/ to 27/8) codes were used to examine trends in amphetamine-related hospital separations: ICD-9 diagnosis ICD-1 diagnosis ICD-9-CM ICD-1-AM Psychostimulant poisoning Poisoning by psychostimulants 9697 T436 (excluding cocaine) Amphetamine & other psychostimulant Stimulant dependence syndrome 344 F152 dependence (methylphenidate, phenmetrazine) Amphetamine or related sympathomimetic use Stimulant acute intoxication 357 F15 disorder Amphetamine or related sympathomimetic use Stimulant harmful use 357 F151 disorder N/A Psychotic disorder N/A F155 Note: Withdrawal codes for ICD-9-CM were not drug specific, and accordingly, for comparability purposes, these separations have been left out of the analysis. 11

Cannabis-related hospital separations The following ICD-9-CM (from 1993/94 to 1998/99) and ICD-1-AM (from 1999/ to 27/8) codes were used to examine trends in cannabis-related hospital separations: ICD-9 diagnosis ICD-1 diagnosis ICD-9-CM ICD-1-AM Cannabis poisoning Cannabis poisoning 9696 T47 Cannabis dependence Cannabis dependence syndrome 343 F122 Cannabis use disorder Cannabinoids acute intoxication 352 F12 Cannabis use disorder Cannabinoids harmful use 352 F121 N/A Psychotic disorder N/A F155 Note: Withdrawal codes for ICD-9-CM were not drug specific, and accordingly, for comparability purposes, these separations have been left out of the analysis. Cocaine-related hospital separations ICD-9 diagnosis ICD-1 diagnosis ICD-9-CM ICD-1-AM Cocaine dependence Cocaine dependence syndrome 342 F142 Cocaine use disorder Cocaine acute intoxication 356 F14 Cocaine use disorder Cocaine harmful use 356 F141 The following ICD-9-CM (from 1993/94 to 1998/99) and ICD-1-AM (from 1999/ to 27/8) codes were used to examine trends in cocaine-related hospital separations: Note: The ICD-9-CM cocaine poisoning code includes procaine, tetracaine and lignocaine poisoning and accordingly, cannot be translated to an ICD-1-AM poisoning code. Withdrawal and drug-induced psychosis codes for ICD-9-CM were not drug specific, and accordingly, for comparability purposes, these separations have been left out of the analysis. Related links: For more information on NDARC research, go to: For more information about the AIHW, go to: For more information on ICD-1, go to: http://ndarc.med.unsw.edu.au/ http://www.aihw.gov.au http://www.who.int/whosis/icd1/ The National Drug and Alcohol Research Centre University of New South Wales Sydney NSW 252 Ph: +61 2 9385 333 Fax: +61 2 9385 222 ISSN: 1834-1918 Recommended citation: Roxburgh, A., and Burns, L. (213). Drug-related hospital stays in Australia, 1993-211. Sydney: National Drug and Alcohol Research Centre 12

References AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE (211) 21 National Drug Strategy Household Survey Report. Canberra, Australian Institute of Health and Welfare. NATIONAL CENTRE FOR CLASSIFICATION IN HEALTH (1998) The International Statistical Classification of Diseases and Related Health Problems, 1th Revision, Australian Modification, Sydney, National Centre for Classification in Health. NATIONAL CODING CENTRE (1996) Australian Verision of the International Classification of Diseases, 9th Revision, Clinical MOdification (ICD-9-CM), Sydney, National Coding Centre. SINDICICH, N. & BURNS, L. (213) Australian trends in ecstasy and related drug markets 212: Findings from the Ecstasy and related Drugs Reporting System (EDRS) Sydney, National Drug and Alcohol Research Centre, UNSW. STAFFORD, J. & BURNS, L. (213) Australian Drug Trends 212: Findings from the Illicit Drug Reporting System (IDRS). Sydney, National Drug and Alcohol Research Centre, UNSW. 13